Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

v3.19.3.a.u2
Intangible Assets (Tables)
12 Months Ended
Sep. 30, 2019
Intangible Assets  
Schedule of intangible assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

    

September 30, 

    

Estimated useful

 

 

2019

 

2018

 

life (in months)

Clinical trial data

 

$

250,000

 

$

 —

 

 6

Accumulated amortization

 

 

(104,167)

 

 

 —

 

  

Intangible assets, net

 

$

145,833

 

$

 —